Alexion Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Alexion Pharmaceuticals, Inc. (ALXN)

Q4 2011 Earnings Call

February 9, 2012 10:00 am ET

Executives

Leonard Bell – Chief Executive Officer

Thomas Dubin – Senior Vice President and Chief Legal Officer

Vikas Sinha – Senior Vice President and Chief Financial Officer

David Hallal – Senior Vice President, Global Commercial Operations

Stephen Squinto – Executive Vice President and Head of Research & Development

Analysts

Rachel McMinn – Bank of America-Merrill Lynch

Eric Schmidt – Cowen and Company

Geoff Meacham – JPMorgan

Yogesh Ahuja – Goldman Sachs & Co.

David Friedman – Morgan Stanley

Salveen Richter – Collins Stewart Llc

Geoffrey Porges – Sanford C. Bernstein & Co. LLC

Matt M. Roden – UBS Securities LLC

Brian Abrahams – Wells Fargo Securities

M Ian Somaiya – Piper Jaffray

Howard Liang – Leerink Swann Llc

Bret Holley – Oppenheimer & Co.

Presentation

Operator

Compare to:
Previous Statements by ALXN
» Alexion Pharmaceutical CEO Discusses Q3 2011 Results - Earnings Call Transcript
» Alexion Pharmaceuticals' CEO Discusses FDA Approval of Soliris as a Treatment for Patients with aHUS - Conference Call
» Alexion Pharmaceuticals CEO Discusses Q2 2011 Results - Earnings Call Transcript
» Alexion Pharmaceuticals Q4 2008 Earnings Call Transcript

Good day, ladies and gentlemen, and welcome to the Alexion Pharmaceutical’s Fourth Quarter 2011 Results Conference Call. My name is Alisha and I will be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of your conference. (Operator Instructions) As a reminder, this conference is being recorded for replay purposes.

I’d now like to introduce Dr. Leonard Bell. Please proceed, sir.

Leonard Bell

Thank you, Alisha. Good morning. Thank you for joining us on today’s call to discuss Alexion’s performance for the fourth quarter and full year 2011.